ITRAQ-based proteomic profiling of human serum reveals down-regulation of platelet basic protein and apolipoprotein B100 in patients with hematotoxicity induced by chronic occupational benzene exposure

Toxicology

Volumn 291, Issue 1-3, 2012, Pages 56-64

  Huang, Zhenlie ^a   Wang, Hailan ^a   Huang, Hanlin ^a   Xia, Lihua ^a   Chen, Cishan ^a   Qiu, Xinxiang ^a   Chen, Jiabin ^a   Chen, Susheng ^a   Liang, Weihui ^a   Huang, Ming ^a   Lang, Li ^a   Zheng, Qianling ^a   Wu, Banghua ^a   Lai, Guanchao ^a  

^a Guangdong Prevention and Treatment Center for Occupational Diseases   (China)

Author keywords

Benzene; Biomarker; ITRAQ; Proteomics; Serum

Indexed keywords

APOLIPOPROTEIN B100; BASIC PROTEIN; BENZENE; PLASMINOGEN;

ADULT; APLASTIC ANEMIA; APOPTOSIS; ARTICLE; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; BLOOD TOXICITY; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME MECHANISM; ENZYME REGULATION; FEMALE; HUMAN; IMMUNITY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LONG TERM EXPOSURE; MALE; MEDICAL RECORD; OCCUPATIONAL EXPOSURE; PANCYTOPENIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEOMICS; SERUM; STIMULUS RESPONSE; TANDEM MASS SPECTROMETRY; THROMBOCYTE; VALIDATION PROCESS; WESTERN BLOTTING;

ADULT; APOLIPOPROTEIN B-100; BENZENE; BETA-THROMBOGLOBULIN; BLOOD CELL COUNT; BLOTTING, WESTERN; CHROMATOGRAPHY, LIQUID; CHRONIC DISEASE; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION PROFILING; HEMATOLOGIC DISEASES; HUMANS; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; PLASMINOGEN; PROTEINS; PROTEOMICS; SOLVENTS; TANDEM MASS SPECTROMETRY;

EID: 84155167895     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2011.10.023     Document Type: Article

References (44)

1. Aggarwal K., Choe L.H., Lee K.H. Shotgun proteomics using the iTRAQ isobaric tags. Brief Funct. Genomic Proteomic 2006, 5:112-120.
2. Aksoy M. Malignancies due to occupational exposure to benzene. Am. J. Ind. Med. 1985, 7:395-402.
3. Anderson N.L., Polanski M., Pieper R., Gatlin T., Tirumalai R.S., Conrads T.P., Veenstra T.D., Adkins J.N., Pounds J.G., Fagan R., Lobley A. The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol. Cell. Proteomics 2004, 3:311-326.
4. Austin H., Delzell E., Cole P. Benzene and leukemia. A review of the literature and a risk assessment. Am. J. Epidemiol. 1988, 127:419-439.
5. Barr R.D., Ouna N., Kendall A.G. The blood coagulation and fibrinolytic enzyme systems in healthy adult Africans and Europeans-a comparative study. Scott. Med. J. 1973, 18:93-97.
6. Begg G.S., Pepper D.S., Chesterman C.N., Morgan F.J. Complete covalent structure of human beta-thromboglobulin. Biochemistry 1978, 17:1739-1744.
7. Ben-Baruch A., Bengali K., Tani K., Xu L., Oppenheim J.J., Wang J.M. IL-8 and NAP-2 differ in their capacities to bind and chemoattract 293 cells transfected with either IL-8 receptor type A or type B. Cytokine 1997, 9:37-45.
8. Biland L., Duckert F., Prisender S., Nyman D. Quantitative estimation of coagulation factors in liver disease. The diagnostic and prognostic value of factor XIII, factor V and plasminogen. Thromb. Haemost. 1978, 39:646-656.
9. Brugger D., Schuster H., Zöllner N. Familial hypercholesterolemia and familial defective apolipoprotein B-100: comparison of the phenotypic expression in 116 cases. Eur. J. Med. Res. 1996, 1:383-386.
10. Colquhoun D.R., Goldman L.R., Cole R.N., Gucek M., Mansharamani M., Witter F.R., Apelberg B.J., Halden R.U. Global screening of human cord blood proteomes for biomarkers of toxic exposure and effect. Environ. Health Perspect. 2009, 117:832-838.
11. Ehlert J.E., Ludwig A., Grimm T.A., Lindner B., Flad H.D., Brandt E. Down-regulation of neutrophil functions by the ELR(+) CXC chemokine platelet basic protein. Blood 2000, 96:2965-2972.
12. Gallimore M.J., Aasen A.O., Erichsen N.S., Larsbraaten M., Lyngaas K., Amundsen E. Plasminogen concentrations and functional activities and concentrations of plasmin inhibitors in plasma samples from normal subjects and patients with septic shock. Thromb. Res. 1980, 18:601-608.
13. Grace C.S., Goldrick R.B. Fibrinolysis and body build, Interrelationships between blood fibrinolysis, body composition and parameters of lipid and carbohydrate metabolism. J. Atheroscler. Res. 1968, 8:705-719.
14. Han Z.C., Lu M., Li J., Defard M., Boval B., Schlegel N., Caen J.P. Platelet factor 4 and other CXC chemokines support the survival of normal hematopoietic cells and reduce the chemosensitivity of cells to cytotoxic agents. Blood 1997, 89:2328-2335.
15. Hayes R.B., Yin S.N., Dosemeci M., Li G.L., Wacholder S., Chow W.H., Rothman N., Wang Y.Z., Dai T.R., Chao X.J., Jiang Z.L., Ye P.Z., Zhao H.B., Kou Q.R., Zhang W.Y., Meng J.F., Zho J.S., Lin X.F., Ding C.Y., Li C.Y., Zhang Z.N., Li D.G., Travis L.B., Blot W.J., Linet M.S. Mortality among benzene-exposed workers in China. Environ. Health Perspect. 1996, 104:1349-1352.
16. Hayes R.B., Yin S.N., Dosemeci M., Li G.L., Wacholder S., Travis L.B., Li C.Y., Rothman N., Hoover R.N., Linet M.S. Benzene and the dose-related incidence of hematologic neoplasms in China, Chinese Academy of Preventive Medicine-National Cancer Institute Benzene Study Group. J. Natl. Cancer Inst. 1997, 89:1065-1071.
17. Hellgren M., Blombäck M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. I. Normal condition. Gynecol. Obstet. Invest. 1981, 12:141-154.
18. Holt J.C., Niewiarowski S. Biochemistry of alpha granule proteins. Semin. Hematol. 1985, 22:151-163.
19. Huang Z., Ichihara S., Oikawa S., Chang J., Zhang L., Takahashi M., Subramanian K., Mohideen S.S., Wang Y., Ichihara G. Proteomic analysis of hippocampal proteins of F344 rats exposed to 1-bromopropane. Toxicol. Appl. Pharmacol. 2011, 10.1016/j.taap. 2011.08.023.
20. International Agency for Research on Cancer (IARC) Benzene. Occupational exposures in petroleum refining; crude oil and major petroleum fuels. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. IARC Monogr. Eval. Carcinog. Risks Hum. 1989, 45:1-322.
21. Joo W.A., Kang M.J., Son W.K., Lee H.J., Lee D.Y., Lee E., Kim C.W. Monitoring protein expression by proteomics: human plasma exposed to benzene. Proteomics 2003, 3:2402-2411.
22. Kuang S., Liang W. Clinical analysis of 43 cases of chronic benzene poisoning. Chem. Biol. Interact. 2005, 153-154:129-135.
23. Lan Q., Zhang L., Li G., Vermeulen R., Weinberg R.S., Dosemeci M., Rappaport S.M., Shen M., Alter B.P., Wu Y., Kopp W., Waidyanatha S., Rabkin C., Guo W., Chanock S., Hayes R.B., Linet M., Kim S., Yin S., Rothman N., Smith M.T. Hematotoxicity in workers exposed to low levels of benzene. Science 2004, 306:1774-1776.
24. Lee H.J., Lee D.Y., Joo W.A., Sul D., Lee E., Kim C.W. Differential expression of proteins in rat plasma exposed to benzene. Proteomics 2004, 4:3498-3504.
25. Markarian M., Githens J.H., Jackson J.J., Bannon A.E., Lindley A., Rosenblut E., Martorell R., Lubchenco L.O. Fibrinolytic activity in premature infants. Relationship of the enzyme system to the respiratory distress syndrome. Am. J. Dis. Child. 1967, 113:312-321.
26. Molinas F.C., Kordich L., Porterie P., Lerer G., Maiztegui J.I. Plasminogen abnormalities in patients with Argentine hemorrhagic fever. Thromb. Res. 1987, 48:713-720.
27. Preston F.E., Burakowski B.K., Porter N.R., Malia R.G. The fibrinolytic response to stanozolol in normal subjects. Thromb. Res. 1981, 22:543-551.
28. Qu Q., Shore R., Li G., Jin X., Chen L.C., Cohen B., Melikian A.A., Eastmond D., Rappaport S.M., Yin S., Li H., Waidyanatha S., Li Y., Mu R., Zhang X., Li K. Hematological changes among Chinese workers with a broad range of benzene exposures. Am. J. Ind. Med. 2002, 42:275-285.
29. Rennie J.A., Bewsher P.D., Murchison L.E., Ogston D. Coagulation and fibrinolysis in thyroid disease. Acta Haematol. 1978, 59:171-177.
30. Ross D. Metabolic basis of benzene toxicity. Eur. J. Haematol. 1996, 60(Suppl.):111-1118.
31. Ross P.L., Huang Y.N., Marchese J.N., Williamson B., Parker K., Hattan S., Khainovski N., Pillai S., Dey S., Daniels S., Purkayastha S., Juhasz P., Martin S., Bartlet-Jones M., He F., Jacobson A., Pappin D.J. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 2004, 3:1154-1169.
32. Rothman N., Li G.L., Dosemeci M., Bechtold W.E., Marti G.E., Wang Y.Z., Linet M., Xi L.Q., Lu W., Smith M.T., Titenko-Holland N., Zhang L.P., Blot W., Yin S.N., Hayes R.B. Hematotoxicity among Chinese workers heavily exposed to benzene. Am. J. Ind. Med. 1996, 29:236-246.
33. 609C→T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res. 1997, 57:2839-2842.
34. Savitz D.A., Andrews K.W. Review of epidemiologic evidence on benzene and lymphatic and hematopoietic cancers. Am. J. Ind. Med. 1997, 31:287-295.
35. Schrader J., Gallimore M.J., Eisenhauer T., Isemer F.E., Schoel G., Warneke G., Brüggeman M., Scheler F. Parameters of the Kallikrein-kinin, coagulation and fibrinolytic system as early indicators of kidney transplant rejection. Nephron 1988, 48:183-189.
36. Shen H., Damcott C.M., Rampersaud E., Pollin T.I., Horenstein R.B., McArdle P.F., Peyser P.A., Bielak L.F., Post W.S., Chang Y.P., Ryan K.A., Miller M., Rumberger J.A., Sheedy P.F., Shelton J., O'Connell J.R., Shuldiner A.R., Mitchell B.D. Familial defective apolipoprotein B-100 and increased low-density lipoprotein cholesterol and coronary artery calcification in the old order amish. Arch. Intern. Med. 2010, 170:1850-1855.
37. Sutor A.H. Bleeding complications in acute myeloblastic leukemia (author's transl). Klin. Padiatr. 1979, 191:217-224.
38. Tait R.C., Walker I.D., Conkie J.A., Islam S.I., McCall F., Mitchell R., Davidson J.F. Plasminogen levels in healthy volunteers-influence of age, sex, smoking and oral contraceptives. Thromb. Haemost. 1992, 68:506-510.
39. Thomas P.D., Campbell M.J., Kejariwal A., Mi H., Karlak B., Daverman R., Diemer K., Muruganujan A., Narechania A. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res. 2003, 13:2129-2141.
40. Vermeulen R., Lan Q., Zhang L., Gunn L., McCarthy D., Woodbury R.L., McGuire M., Podust V.N., Li G., Chatterjee N., Mu R., Yin S., Rothman N., Smith M.T. Decreased levels of CXC-chemokines in serum of benzene-exposed workers identified by array-based proteomics. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:17041-17046.
41. Walz A., Baggiolini M. Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases. J. Exp. Med. 1990, 171:449-454.
42. Wenger R.H., Wicki A.N., Walz A., Kieffer N., Clemetson K.J. Cloning of cDNA coding for connective tissue activating peptide III from a human platelet-derived lambda gt11 expression library. Blood 1989, 73:1498-1503.
43. Yin S.N., Hayes R.B., Linet M.S., Li G.L., Dosemeci M., Travis L.B., Zhang Z.N., Li D.G., Chow W.H., Wacholder S., Blot W.J. An expanded cohort study of cancer among benzene-exposed workers in China. Benzene Study Group. Environ. Health Perspect. 1996, 104:1339-1341.
44. Zhang H., Ding L., Fang X., Shi Z., Zhang Y., Chen H., Yan X., Dai J. Biological responses to perfluorododecanoic acid exposure in rat kidneys as determined by integrated proteomic and metabonomic studies. PLoS One 2011, 6:e20862.